KAMPALA - Dr Matthias Magoola says the US Patent and Trademark Office (USPTO) has granted a patent for his invention of the first treatment of cancer using a novel composition of a guided Ribonucleic ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...

It also touts the non-FDA-approved Hims & Hers weight-loss drug as the supreme and affordable solution to America’s obesity ...

An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune ...

Today, adoption of digital health faces some of the same barriers — scepticism, budget limitations, high expectations, and a ...

Moleculin Biotech has received approval in Ukraine to begin enrolment in its trial of annamycin with cytarabine for acute ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s disease. NKGen will benefit from increased FDA interactions, ...

Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and ...